Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 3
2005 1
2006 1
2007 2
2009 1
2010 1
2012 2
2013 2
2015 2
2018 1
2019 1
2020 1
2021 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Lentigo maligna: diagnosis and treatment.
De Luca EV, Perino F, Di Stefani A, Coco V, Fossati B, Peris K. De Luca EV, et al. G Ital Dermatol Venereol. 2020 Apr;155(2):179-189. doi: 10.23736/S0392-0488.18.06003-0. Epub 2018 Apr 19. G Ital Dermatol Venereol. 2020. PMID: 29683288 Free article. Review.
Lentigo maligna (LM) is an in situ subtype of melanoma, clinically presenting as a pigmented, asymmetric macule that originates mostly on the head and neck and spreads slowly. ...Dermatoscopy and reflectance confocal microscopy represent a useful tool in the differentiatio …
Lentigo maligna (LM) is an in situ subtype of melanoma, clinically presenting as a pigmented, asymmetric macule that originates mostl …
Efficacy of imiquimod in the management of lentigo maligna.
Daude M, Dinulescu M, Nguyen JM, Maillard H, Le Duff F, Machet L, Beylot-Barry M, Legoupil D, Wierzbicka-Hainaut E, Bedane C, Leccia MT, Debarbieux S, Meyer N, Monestier S, Bens G, Denis MG, Bossard C, Vergier B, Khammari A, Dréno B. Daude M, et al. J Eur Acad Dermatol Venereol. 2023 Sep;37(9):1785-1791. doi: 10.1111/jdv.19141. Epub 2023 May 6. J Eur Acad Dermatol Venereol. 2023. PMID: 37114291 Clinical Trial.
Excision margins of 5-10 mm remain, without international consensus. Several studies have shown that imiquimod, an immunomodulator, induces LM regression. This study investigated the effect of imiquimod versus placebo in neoadjuvant settings. ...The primary endpoint …
Excision margins of 5-10 mm remain, without international consensus. Several studies have shown that imiquimod, an immunomodulator, i …
Lentigo maligna: review of salient characteristics and management.
Kallini JR, Jain SK, Khachemoune A. Kallini JR, et al. Am J Clin Dermatol. 2013 Dec;14(6):473-80. doi: 10.1007/s40257-013-0044-6. Am J Clin Dermatol. 2013. PMID: 24019181 Review.
Lentigo maligna is a melanocytic neoplasm, often regarded as 'melanoma in situ,' which may progress to lentigo maligna melanoma. Lentigo maligna clinically presents as a pigmented, asymmetric macule that originates on the head and neck and spreads slowly. ...Surgical excis …
Lentigo maligna is a melanocytic neoplasm, often regarded as 'melanoma in situ,' which may progress to lentigo maligna melanoma. Lentigo mal …
Long-term outcomes of imiquimod-treated lentigo maligna.
Papanikolaou M, Lawrence CM. Papanikolaou M, et al. Clin Exp Dermatol. 2019 Aug;44(6):631-636. doi: 10.1111/ced.13896. Epub 2019 Jan 20. Clin Exp Dermatol. 2019. PMID: 30663131
AIM: To assess long-term outcomes of LM treated with imiquimod cream. METHODS: We collected data retrospectively for 33 patients treated with imiquimod cream for biopsy-proven LM from 2001 to 2016. ...With adequate patient preparation, imiquimod is generally …
AIM: To assess long-term outcomes of LM treated with imiquimod cream. METHODS: We collected data retrospectively for 33 patients trea …
Series of Fourteen Cases of Topical Imiquimod 5% in Lentigo Maligna: Treatment Modalities and Clues for Detecting Recurrences.
Poveda-Montoyo I, Álvarez-Chinchilla P, Schneller-Pavelescu L, Hispán-Ocete P, Bañuls-Roca J. Poveda-Montoyo I, et al. Actas Dermosifiliogr. 2022 Apr;113(4):T407-T412. doi: 10.1016/j.ad.2021.07.012. Epub 2021 Dec 3. Actas Dermosifiliogr. 2022. PMID: 35623739 Free article. English, Spanish.
Topical imiquimod has been used off-label as monotherapy or adjuvant treatment for lentigo maligna. ...Imiquimod appears to be a versatile option for treating LM in suitable candidates....
Topical imiquimod has been used off-label as monotherapy or adjuvant treatment for lentigo maligna. ...Imiquimod appears to be …
Imiquimod as an antiaging agent.
Metcalf S, Crowson AN, Naylor M, Haque R, Cornelison R. Metcalf S, et al. J Am Acad Dermatol. 2007 Mar;56(3):422-5. doi: 10.1016/j.jaad.2006.10.034. Epub 2006 Dec 20. J Am Acad Dermatol. 2007. PMID: 17184874 Clinical Trial.
BACKGROUND: Topical imiquimod therapy has proven to be effective for a variety of infectious, neoplastic, and inflammatory dermatologic diseases. ...There is, however, limited evidence demonstrating the use of topical imiquimod application as an antiaging treatment. …
BACKGROUND: Topical imiquimod therapy has proven to be effective for a variety of infectious, neoplastic, and inflammatory dermatolog …
Lentigo maligna: current concepts in diagnosis and management.
Walling HW. Walling HW. G Ital Dermatol Venereol. 2009 Apr;144(2):149-55. G Ital Dermatol Venereol. 2009. PMID: 19357622 Review.
Early diagnosis of LM requires a high index of suspicion for the often subtle atypical signs of pigmented lesions on sun-damaged skin. A variety of treatment options are available to the physician. ...Topical therapy may be appropriate in selected cases; immunotherapy with …
Early diagnosis of LM requires a high index of suspicion for the often subtle atypical signs of pigmented lesions on sun-damaged skin …
New approaches to surgery of lentigo maligna.
Huang CC. Huang CC. Skin Therapy Lett. 2004 May;9(5):7-11. Skin Therapy Lett. 2004. PMID: 15146261 Free article. Review.
Lentigo maligna (LM) is a pigmented lesion that occurs most commonly on the sun-exposed skin of the head and neck of an older patient. ...Immunostains that can increase sensitivity and specificity of margin-controlled excision are discussed, and other nonscalpel treatments …
Lentigo maligna (LM) is a pigmented lesion that occurs most commonly on the sun-exposed skin of the head and neck of an older patient …
Surgical and histologic pitfalls in the management of lentigo maligna melanoma.
Situm M, Buljan M. Situm M, et al. G Ital Dermatol Venereol. 2012 Feb;147(1):21-7. G Ital Dermatol Venereol. 2012. PMID: 22370566 Review.
Lentigo maligna (LM) is LMM in situ, usually presenting an irregular tan colored or brownish pigmented macular lesion persisting for years on chronically sun-exposed skin. ...Non-surgical treatment modalities for LM include: destructive procedures such radiotherapy, cryoth …
Lentigo maligna (LM) is LMM in situ, usually presenting an irregular tan colored or brownish pigmented macular lesion persisting for …
Series of Fourteen Cases of Topical Imiquimod 5% in Lentigo Maligna: Treatment Modalities and Clues for Detecting Recurrences.
Poveda-Montoyo I, Álvarez-Chinchilla P, Schneller-Pavelescu L, Hispán-Ocete P, Bañuls-Roca J. Poveda-Montoyo I, et al. Actas Dermosifiliogr. 2022 Apr;113(4):407-412. doi: 10.1016/j.ad.2021.07.018. Epub 2022 Mar 4. Actas Dermosifiliogr. 2022. PMID: 35431054 Free article. English, Spanish.
Topical imiquimod has been used off-label as monotherapy or adjuvant treatment for lentigo maligna. ...Imiquimod appears to be a versatile option for treating LM in suitable candidates....
Topical imiquimod has been used off-label as monotherapy or adjuvant treatment for lentigo maligna. ...Imiquimod appears to be …
19 results